Stockscreener 앱 받기
1.30
2.99%
-0.04
시간 외 거래:
1.30
전일 마감가:
$1.34
열려 있는:
$1.329
하루 거래량:
5.52M
Relative Volume:
0.64
시가총액:
$440.08M
수익:
$4.41M
순이익/손실:
$-67.85M
주가수익비율:
-5.7573
EPS:
-0.2258
순현금흐름:
$-57.15M
1주 성능:
-11.56%
1개월 성능:
-34.67%
6개월 성능:
+14.04%
1년 성능:
+68.88%
1일 변동 폭
$1.27
$1.34
1주일 범위
$1.27
$1.49
52주 변동 폭
$0.733
$2.725
오큐젠 Stock (OCGN) Company Profile
명칭
Ocugen Inc
전화
484-328-4701
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.30 | 453.62M | 4.41M | -67.85M | -57.15M | -0.2258 |
VRTX
Vertex Pharmaceuticals Inc
|
434.31 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
630.30 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
797.77 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.30 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
147.30 | 30.69B | 742.00K | -1.37B | -1.07B | -7.0731 |
오큐젠 Stock (OCGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 개시 | Canaccord Genuity | Buy |
| 2026-03-11 | 개시 | Oppenheimer | Outperform |
| 2024-10-15 | 개시 | Maxim Group | Buy |
| 2023-03-01 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 개시 | Mizuho | Buy |
| 2022-06-15 | 재개 | ROTH Capital | Buy |
| 2022-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 개시 | Noble Capital Markets | Outperform |
| 2021-06-11 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
모두보기
오큐젠 주식(OCGN)의 최신 뉴스
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Q4 2025 Ocugen Inc Earnings Call Transcript - GuruFocus
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen closes $130 million convertible notes offering - Investing.com UK
Gene therapy pipeline accelerates as Ocugen, Inc. targets approvals for RP and Stargardt disease - Traders Union
Ocugen Raises $130 Million Through Convertible Notes Offering - TipRanks
Ocugen Announces Interim Chief Medical Officer Appointment Transition - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes - Ocugen, Inc.
Has Ocugen's Recent Convertible Notes Offering Stabilized Its Financial Future - Kavout
Ocugen closes $130 million convertible notes offering By Investing.com - Investing.com Australia
Ocugen Reports Positive GA Trial Data, Extends Cash Runway - MyChesCo
Ocugen (NASDAQ: OCGN) shifts CMO duties to interim leader - Stock Titan
Ocugen (NASDAQ: OCGN) closes $130M 6.75% convertible notes due 2034 - Stock Titan
$130M bet on blindness gene therapies: Ocugen raises cash, clears loan, backs 3 late-stage programs - Stock Titan
Ocugen signs license deal with Korean company for gene therapy - MSN
Ocugen issues $115M notes to repay debt; stock faces after-hours selling - MSN
Ocugen to Participate in Upcoming May Scientific and Investor Conferences - Sahm
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally - The Motley Fool
Ocugen’s Convertible Cash and Reverse Split Vote Set the Table for a Triple-Data Summer - AD HOC NEWS
Ocugen, Inc. to Present Innovative Modifier Gene Therapy Platform at May 2026 Conferences - Quiver Quantitative
OCGN Stock Chart | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Ocugen (OCGN) Reports Q1 EPS - Insider Monkey
Ocugen’s Clinical Calendar Packs a Punch in Q3 as Analysts Stay Bullish on Gene Therapy Pipeline - AD HOC NEWS
5 Best Penny Stocks to Buy Before They Explode - Insider Monkey
Ocugen stock (US67577C1053): Q1 2026 earnings miss sparks stock drop - AD HOC NEWS
Ocugen, Inc. advances automation in quantitative autofluorescence for geographic atrophy at ARVO2026 - Traders Union
Earnings call transcript: Ocugen Q1 2026 earnings miss triggers stock drop By Investing.com - Investing.com South Africa
Earnings call transcript: Ocugen Q1 2026 earnings miss triggers stock drop - Investing.com
Ocugen, Inc.Common Stock (NQ: OCGN - FinancialContent
H.C. Wainwright Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Ocugen’s $115 Million Convertible Lifeline Buys Time, but Pipeline Proof Remains the Prize - AD HOC NEWS
Ocugen stock dips as Q1 losses widen - MSN
Ocugen (OCGN) Is Down 16.8% After $115M Convertible Notes Deal And Wider Q1 Losses Has The Bull Case Changed? - Yahoo Finance
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen (OCGN) Upgraded to Buy: Here's Why - Yahoo Finance
Ocugen’s Convertible Lifeline Fuels a Three-Pronged Gene Therapy Sprint - AD HOC NEWS
Ocugen (NASDAQ: OCGN) posts larger Q1 2026 loss and raises $115M in convertible notes - Stock Titan
Number of shareholders of Ocugen Inc – LSX:A2PSZH - TradingView
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Ocugen Raises Capital Through Convertible Senior Notes Offering - TipRanks
Ocugen (NASDAQ: OCGN) sells $115M 2034 convertibles, retires Avenue loan - Stock Titan
Chardan Capital Initiates Ocugen(OCGN.US) With Buy Rating, Announces Target Price $7 - Moomoo
Ocugen’s $115 Million Convertible Lifeline Buys Time, but Investors Want Pipeline Proof - AD HOC NEWS
Ocugen’s $115 Million Convertible Bet Raises the Stakes for a Trio of Gene Therapy Trials - AD HOC NEWS
오큐젠 (OCGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.19%
0.65%
자본화:
|
볼륨(24시간):